• Akram M. El-didamony Chemistry Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt
  • Monuir Z. Saad Chemistry Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt
  • Nora O. Saleem Chemistry Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt


Objective: To develop and validate simple, rapid and sensitive spectrophotometric method for the assay of four antimuscarinic antagonists, namely oxybutynin (OXB), solifenacin (SOL), tolterodine (TOL) and fesoterodine (FES) in bulk and pharmaceutical formulations.

Methods: The proposed method is based on the reaction of the selected drugs with eriochrome cyanine R (ECR) in buffered aqueous solution at pH 1.0. The formed ion-pair complexes were extracted with dichloromethane and measured quantitatively with maximum absorption at 464 nm. All variables that affect on color intensity such as pH, buffer volume and concentration of ECR and extractive solvents were studied and optimized.

Results: The calibration graphs were linear over the concentration range of 4–24, 4–32, 4–32 and 2–22 mg/ml for OXB, SOL, TOL and FES, respectively. The stoichiometry of the reaction was found to be 1:1 in all cases. Molar absorptivity values were found to be 2.043×104, 1.856×104, 1.798×104 and 2.856×104 l/mol/cm for OXB, SOL, TOL and FES, respectively. Excipients which used as an additive in commercial formulations did not interfere in the analysis.

Conclusion: The developed method was successfully applied to determine OXB, SOL, TOL and FES in pharmaceutical preparations. The developed method can be used for quality control and routine analysis where time, cost effectiveness and high specificity of analytical technique are of great importance.

Keywords: Spectrophotometry, Ion-pair complexes, Oxybutynin chloride, Solifenacin, Tolterodine, Fesoterodine, Eriochrome cyanine R


Download data is not yet available.


1. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine–a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207.
2. Jacquetin B, Wyndaele JJ. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gyn RB 2001;98:97-102.
3. Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Therap 2007;81:377-85.
4. Diokno AC, Lapides J. Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972;108:307-9.
5. Lish PM, Labudde JA, Peters EL, Robbins SI. Oxybutynin-a musculotropic antispasmodic drug with moderate anticholinergic action. Arch Int Pharm Ther 1965;156:467-88.
6. Fredericks CM, Anderson GF, Kreulen DL. A study of the anticholinergic and antispasmodic activity of oxybutynin (Ditropan) on rabbit detrusor. Invest Urol 1975;12:317-9.
7. Varma MVS, Kaushal AM, Garg S. Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations. J Pharm Biomed Anal 2004;36:669-74.
8. Wagieh NE, Hegazy MA, Abdelkawy M, Abdelaleem EA. Quantitative determination of oxybutynin hydrochloride by spectrophotometry, chemometry and HPTLC in presence of its degradation product and additives in different pharmaceutical dosage forms. Talanta 2010;80:2007-15.
9. Srikanth K, Emmanuel KA, Ramesh Raju K. Spectrophotometric determination of oxybutynin chloride through ion-association complex formation. Rasayan J Chem 2010;3:179-87.
10. Jain R, Radhapyari K, Jadon N.‏ Adsorptive stripping voltammetric behavior and determination of anticholinergic agent oxybutynin chloride on a mercury electrode. J Colloid Interface Sci 2007;314:572-7.
11. El-Gindy A. High-performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products. IL Farmaco 2005;60:689-99.
12. da Fonseca P, de Freitas LAP, Pinto LFR, Pestana CR, Bonato PS. Enantioselective analysis of oxybutynin and Ndesethyloxy-butynin with application to an in vitro biotransformation study. J Chromatogr B 2008;875:161-7.
13. Guo N, Gao X, Xu G, Guo X. High-performance liquid chromatographic separation of oxybutynin enantiomers using chiral mobile phase additive. Sepu 2008;26:259-61.
14. Ding X, Gao S, Cao Q, Miao C, Zhong Y, Yu Y, et al. Reversed-phase high performance liquid chromatographic determination of oxybutynin hydrochloride in its tablets. Dier Junyi Daxue Xuebao 2003;24:327-9.
15. Lindeke B, Brötell H, Karlen B, Rietz G, Vietorisz A. Determination of oxybutynin (4-diethylaminobut-2-ynyl 2-cyclohexyl-2-phenylglycolate) in serum and urine by gas chromatography/mass spectrometry with single ion detection. Acta Pharm Suec 1981;18:25-34.
16. Michelitsch A, Likussar W, Schubert-Zsilavecz M. Determination of oxybutynin hydrochloride by differential pulse polarography. Monatsh Chem 1994;125:1183-7.
17. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐and tolterodine‐controlled phase 2 dose‐finding study. BJU Int 2004;93:71-7.
18. Cardozo L, Lisec M, Millard R, Van Vierssen, Trip O, Kuzmin I, et al. Randomized, double-blind placebo-controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24.
19. Ramandeep B, Con K. A review of solifenacin in the treatment of urinary incontinence. Ther Clin Risk Manag 2008;4:117-28.
20. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24.
21. Reddy BVR, Reddy BS, Raman NVVSS, Reddy KS, Rambabu C. Development and validation of a specific stability indicating high performance liquid chromatographic methods for related compounds and assay of solifenacin succinate. J Chem 2012;2013:1-10.
22. Desai D, Patel G, Shukla N, Rajput S. Development and validation of stability-indicating HPLC method for solifenacin succinate: isolation and identification of major base degradation product. Acta Chromatogr 2012;24:399-418.
23. Annapurna MM, Sowjanya G, Naidu MS, Lohithasu D. A validated a liquid chromatographic method for the determination of solifenacin succinate (UrinaryAntispasmodic) in tablets. Chem Sci Trans 2014;3:602-7.
24. Kumar RS, kumar BVVR, Kumar PA. A RP-HPLC method development and validation for the estimation of solifenacin in bulk and pharmaceutical dosage forms. Int J Bioassays 2012;1:210-3.
25. Krishna SR, Rao BM, Rao NS. A validated a rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. J Chromatogr Sci 2010;48:807-10.
26. Vijayasree AV, Anantha kumar AD, Seshagiri Rao BJVLN. Validated RP-HPLC method for the estimation of solifenacin succinate in tablet dosage forms. Pharmanest 2013;4:206-12.
27. Israel DS, Krishnachaitanya K, GowriSankar D. RP-HPLC method for the estimation of tamsulosin and solifenacin in bulk and its dosage forms. Int J Pharm Sci Res 2013;4:4343-50.
28. Teja GD, Dasu CHD, Srinivasa BP, Ravisankar P. Quantitative analysis of solifenacin succinate in pharmaceutical dosage form using UV absorption spectroscopy. J Chem Pharm Sci 2013; 6:195-8.
29. Seetharaman R, Lakshmi KS. Development and validation of first-order derivative spectrophotometric method for estimation of solifenacin succinate in a pharmaceutical formulation. Int J Res Pharm Biomed Sci 2011;2:1052-7.
30. Nanda RK, Gaikwad J, Prakash A. Estimation of tamsulosin and tolterodine in its pharmaceutical dosage form by spectrophotometric method. Int J Pharm Tech Res 2009;1:420-3.
31. Shetty SK, Shah A. New spectrophotometric method for estimation of tolterodine in bulk and pharmaceutical formulation. Int J Pharm Sci Res 2011;2:1456-8.
32. Fraihat SM, Khatib HS. Indirect spectrophotometric determination of tolterodine tartrate in pure and pharmaceutical preparations. Asian J Chem 2013;25:1887-90.
33. El-Sheikh R, Hassan WS, Gouda AA, El-Gabry MM. Sensitive spectrophotometric assay of muscarinic receptor antagonist tolterodine tartrate in bulk drug and pharmaceutical formulations. Asian J Pharm Clin Res 2017;10:346-52.
34. Madhavi A, Reddy GS, Suryanarayana VM, Naidu A. A development and validation of a new analytical method for the determination of related components in tolterodine tartarate using LC. Chromatographia 2008;86:399-407.
35. Macek J, Ptacek P, Klima J. Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J Chromatogr B 2009;877:968-74.
36. Yadav M, Upadhyay V, Chauhan V, Solanki G, Jani A, Baxi GA, et al. LC–MS–MS Separation and simultaneous determination of tolterodine and its active metabolite, 5-Hydroxymethyl tolterodine in human plasma. Chromatographia 2010;72:255-64.
37. Siddartha B, Sudheer Babu I, Racichandra Gupta Ch, Parthiban C. Analytical method development and validation for simultaneous estimation of tamsulosin and tolterodine in bulk and pharmaceutical dosage form by the RP-HPLC method. Asian J Pharm Clin Res 2014;7:156-60.
38. Xia ZL, Chen ZY, Yao TW. An enantiospecific HPLC method for the determination of (S)–enantiomer impurities in (R)-tolterodine tartarate. Pharmazie 2007;62:170-3.
39. Radhakrishna S, Rao BM, Rao NS. A validated stability-indicating HPLC method for the determination of related substances and assay of tolterodine tartarate. Rasáyan J Chem 2009;2:144-50.
40. Sinha VR, Jindal V, Kumar RV, Bhinge JR, Goel H. Development and validation of a simple, stability-indicating high-performance liquid chromatographic method for analysis of tolterodine tartrate in the bulk drug and in its tablet formulation. Acta Chromatogr 2011;23:133-43.
41. Ramathilagam N, Meeradevi M, Solairaj P, Rajesh SC. Development and validation of HPLC method for the estimation of tolterodine tartrate in tablets. Int J Pharm Biol Sci 2012;2:332-7.
42. Sakra MM, Nashara RM. Potentiometric determination of tolterodine in batch and flow injection conditions. Talanta 2012;96:153-60.
43. Macikova P, Skopalova J, Cankar P, Papouskova B, Strakova R, Jirovsky D, et al. Electrochemical oxidation of tolterodine. Electroanalysis 2013;25:205-12.
44. Kul D. Sensitive and selective determination of tolterodine tartrate and its electrochemical investigation on solid carbon based electrodes. J Anal Chem 2014;69:970-81.
45. Dmochowski RR, Gomelsky A. Update on the treatment of overactive bladder. Curr Opin Urol 2011;21:286-90.
46. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioral interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 2009;63:1177-91.
47. Sangoi MS, Steppe M. Determination of fesoterodine in pharmaceutical formulations by using liquid chromatography-tandem mass spectrometry. Eur J Mass Spectrom 2010;16:653-61.
48. Sangoi MS, Todeschini V, Steppe M. Fesoterodine stress degradation behavior by liquid chromatography coupled ultraviolet detection and electrospray ionization mass spectrometry. Talanta 2011;84:1068-79.
49. Parekh JM, Sanyal M, Yadav M, Shrivastav PS. Investigation of ex vivo stability of fesoterodine in human plasma and its simultaneous determination together with its active metabolite 5-HMT by LC–ESI-MS/MS: application to a bioequivalence study. J Chromatogr B 2013;913:1-11.
50. Reddy BVR, Reddy BS, Kumar MS, Rambabu C. A validated stability-indicating HPLC assay method for determination of fesoterodine fumarate. Rasáyan J Chem 2012;5:239-45.
51. Kotla NR, Nagaraju ChVS, Rajan ST, Eshwaraiah S, Sampath KRG, Rakesh M, et al. Stability indicating HPLC method for the quantification of fesoterodine fumarate and its related substances. Pharma Chem 2013;5:115-22.
52. Rajput AP, Sonanis MC. Stability indicating HPLC method for the enantiomeric separation of fesoterodine fumarate in drug product and drug substance using chiral stationary phase. J Chem Pharm Res 2012;4:4127-33.
53. Satya T, Yadav GKSS, Chakravarthy IE. New simple UV spectrophotometric determination of paliperidone palmitate in tablets. Int J Eng Sci Res Technol 2014;3:411-3.
54. Thotteti S, Yadav SS, Chakravarthy IE. A simple UV spectrophotometric method for the determination of fesoterodine fumarate in tablets. Int J Pharm Sci Lett 2014;4:413-6.
55. Sangoi MS, Todeschini V, Steppe M. Second-order derivative uv spectrophotometric method for the determination of fesoterodine and comparison with LC, CE and LC-MS/MS in commercial extended-release tablets. Acta Chim Slov 2012;59:136-43.
56. Sangoi MS, Todeschini V, Steppe M. Determination of fesoterodine in a pharmaceutical preparation by a stability-indicating capillary zone electrophoresis method. J AOAC Int 2013;96:1308-14.
57. El-Didamony AM. Extractive spectrophotometric methods for the determination of oxomemazine hydrochloride in bulk and pharmaceutical formulations using bromocresol green, bromocresol purple and bromophenol blue. Arch Der Pharmazie 2005;338:190-7.
58. El-Didamony AM. Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange. Spectrochim Acta A 2008;69:770-5.
59. El-Didamony AM, Mustafa MA. Spectrophotometric determination of diphenhydramine hydrochloride in pharmaceutical preparations and biological fluids via ion-pair formation. Arab J Chem 2010;3:265-70.
60. El-Didamony AM, Shehata AM. Spectrophotometric determination of β-adrenergic antagonists drugs via ion-pair complex formation using MO and EBT. Opt Spectrosc 2014;117:492-9.
61. Miller JC, Miller JN. Significance tests in statistics for analytical chemistry”, 3rd ed. Chap. 3. Hardwood, Chichester; 1993.
332 Views | 780 Downloads
How to Cite
El-didamony, A. M., M. Z. Saad, and N. O. Saleem. “EXTRACTIVE-SPECTROPHOTOMETRIC DETERMINATION OF SOME ANTIMUSCARINIC ANTAGONIST IN TABLET FORMULATIONS USING ERIOCHROME CYANINE R”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 10, no. 4, Apr. 2018, pp. 22-28, doi:10.22159/ijpps.2018v10i4.24300.
Original Article(s)